hexamethylene amiloride

Hexamethylene amiloride is a synthetic derivative of amiloride, structurally defined as the 5-(N,N-hexamethylene) substitution on the amiloride scaffold. Unlike the parent drug, hexamethylene amiloride is researched primarily as a molecular probe and experimental compound rather than as a clinical diuretic. Its principal mechanism centers on the **inhibition of the urokinase-type plasminogen activator (uPA)**, an enzyme implicated in cancer cell invasiveness and metastasis. Hexamethylene amiloride also retains inhibitory activity at acid-sensing ion channels (ASICs) and epithelial sodium channels (ENaC), but some analogs show high selectivity for uPA and minimal diuretic effect. It has been shown to display anti-metastatic activity in preclinical cancer models and has been studied for chemosensitization in acute myeloid leukemia models[6][11][12].

Other names

5-(N,N-hexamethylene)amilorideHMA